Awards and Grants We support collaborative innovation through the endowment of awards and grants to researchers around the world. In FY2025, we contributed $10.3 million to science and innovation to advance knowledge, research and careers in biomedicine. One example is the CSL Centenary Fellowships. Since 2016, CSL has awarded two individual fellowships annually – each valued at A$1.25 million over five years – to early to mid-career medical researchers. These fellowships support discovery and translational medical research and are a key part of CSL’s commitment to fostering a thriving medical research community and advancing Australian science. Advancing Sickle Cell Disease Research Through our HemMa research collaboration in Switzerland, we’re discovering novel insights into the pathophysiology of sickle cell disease (SCD). The research – a collaboration between CSL, the Departments of Haematology of the University Hospitals of Bern and Lausanne and the University of Bern – is helping identify key biomarkers and improve understanding of SCD complications. In addition to shaping our clinical study designs for CSL889 hemopexin (a plasma-based treatment for SCD), we’re sharing the findings at conferences around the world, contributing to enduring patient impact globally. This includes at the American Society of Hematology, the European Hematology Association, and the Swiss Oncology and Hematology Congress. The research team is also preparing two manuscripts, one on transcriptomic profiling and the other on biomarker findings related to SCD. “ I lead a team of medical and scientific experts who have in-depth conversations with leading clinicians to understand how the scientific data translates into benefits for patients. This ensures that the right treatment is prescribed to the right patient at the right time. I’m really proud of the efforts that our team makes.” Claire Morgan, Senior Director, Medical Affairs, CSL Seqirus DR QI ZHANG’S STORY CSL Centenary Fellowship recipient “I’m a group leader at the South Australian Immuno Genomic Cancer Institute at the University of Adelaide. All cells in our body share identical DNA but what makes them different is sets of genes that are turned on and off in different cell types. But these processes are not fully understood. My work is going to study how the different sets of genes turn on and off in both normal development and also in cancer or other diseases. This is epigenetics. We want to know what’s happening in a healthy cell, then we want to know what is going wrong in a cancer cell – when it loses its identity. Using the CSL Centenary Fellowship we hope to have generated fundamental knowledge that researchers around the world can use to develop new drugs. It’s complex work which will use a range of approaches ranging from biochemistry, biophysics, molecular and cell biology, structural biology, genomics and bioinformatics. Here at our institute in Adelaide we will also explore the therapeutic potential of our basic research findings. It’s an exciting time to be a researcher with so many developments in technologies like RNA therapeutics and genomics. I hope that in a decade there will be many more options to fight disease.” 21 Limited Our Impact 2025 About CSL From our CEO Lifesaving Medicines Healthier Communities Legacy Science and Medicine
RkJQdWJsaXNoZXIy MjE2NDg3